Vaccine for U.S. Kids Under 5 Delayed as FDA Stalls Review (1)

A Covid-19 vaccine for children under age 5 is unlikely to be cleared in the U.S. until the spring after federal regulators opted to postpone a review scheduled for next week to wait for more data.

Food and Drug Administration advisers had been planning to consider a two-dose regimen of Pfizer Inc.’s shot on Tuesday. The delay is to allow the company and German partner BioNTech SE to gather and evaluate more information on the impact of a third dose, agency officials said Friday in a statement.

The delay is the latest swerve on the roller-coaster ride for ...